DNA Nanobarrel-Based Drug Delivery for Paclitaxel and Doxorubicin

Area of Science:

• Biotechnology
• Nanotechnology
• Drug Delivery

Background:

• Targeted and synergistic cancer therapy requires co-delivery of anticancer drugs and targeting agents using biocompatible materials.
• DNA nanotechnology offers precise nanoscale positioning and assembly capabilities, with DNA structures being water-soluble, biocompatible, and modifiable for drug delivery.

Purpose of the Study:

• To develop a DNA nanobarrel for the co-delivery of paclitaxel (PTX) and doxorubicin.
• To incorporate a mucin 1 (MUC-1) aptamer for targeted delivery.
• To investigate the impact of single-stranded DNA tail lengths on drug release and cytotoxicity.

Main Methods:

• Conjugation of paclitaxel (PTX) to single-stranded DNA tails.
• Assembly of a DNA nanobarrel carrier.
• Co-loading of PTX, doxorubicin, and MUC-1 aptamer onto the nanobarrel.
• Evaluation of drug release kinetics based on varying tail lengths.
• Assessment of dual drug co-delivery-enabled cytotoxicity.

Main Results:

• Successful co-delivery of PTX, doxorubicin, and MUC-1 aptamer using a DNA nanobarrel.
• Demonstrated influence of DNA tail lengths on drug release efficiencies.
• Observed enhanced cytotoxicity due to dual drug co-delivery.

Conclusions:

• DNA nanostructures are promising carriers for functional drug delivery systems.
• The developed DNA nanobarrel platform facilitates targeted and synergistic cancer therapy.
• Further development in DNA nanotechnology holds potential for clinical therapeutic applications.